MS4A6A

MS4A6A is a member of the MS4A family of tetraspan membrane proteins expressed in microglia, mast cells, and endothelial cells that functions as a post-transcriptional negative regulator of TREM2 signaling and a modulator of inflammatory state (PMID:41435829, PMID:40877951). In microglia and macrophages, MS4A6A forms a complex with the co-receptor DAP12, blocking DAP12-dependent stabilization, surface localization, and signaling of TREM2 and thereby limiting microglial viability, phagocytosis, and lysosomal function; its own stability is maintained by direct interaction with its paralog MS4A4A, which protects it from proteasomal degradation (PMID:41435829). In vivo loss of the mouse ortholog reduces microglial envelopment and phagocytosis of amyloid plaques, increases plaque burden and synaptic damage, and disinhibits NF-κB-driven neuroinflammation, while MS4A6A overexpression promotes plaque-associated gene expression and restrains inflammatory signatures, identifying MS4A6A as a restraint on disease-associated microglial inflammatory states (PMID:40877951). In endothelial cells, MS4A6A acts upstream of the IKK/NF-κB pathway to promote endothelial dysfunction, inflammatory factor and adhesion molecule expression, and monocyte adhesion (PMID:40090082). In mast cells, MS4A6A promotes surface expression of FcεRI complexes and facilitates IgE-mediated degranulation, acting as a compensatory FcεRIβ-like protein when FcεRIβ is absent or reduced (PMID:36424895).

1. 2017 Medium

   Before functional roles were defined, it was unclear how Alzheimer-associated MS4A locus variation altered gene expression; this work showed a risk SNP creates an antioxidant response element driving MS4A6A transcription.

   Evidence Reporter assays with risk vs. reference allele plus NRF1/NRF2 binding validation under proteostatic stress

   PMID:29179108

   Open questions at the time

   • Does not establish the downstream cellular function of elevated MS4A6A
   • Links transcription to stress but not to a specific disease mechanism
2. 2022 Medium

   The cellular function of MS4A6A was unknown; this work established a role in mast cells as a compensatory FcεRIβ-like protein supporting FcεRI surface expression and IgE-mediated degranulation.

   Evidence Exon-skipping of FcεRIβ in human vs. mouse mast cells with degranulation and surface expression readouts

   PMID:36424895

   Open questions at the time

   • Mechanism of FcεRI complex stabilization not defined at the molecular level
   • Relevance to non-mast-cell lineages (microglia, endothelium) not addressed
3. 2024 Medium

   How MS4A proteins regulate TREM2 was unresolved; this preprint established that MS4A6A forms a complex with DAP12 to restrain TREM2 and that MS4A4A protects MS4A6A from degradation, negatively regulating microglial proliferation, metabolism, and phagocytosis.

   Evidence CRISPR KO and MS4A4A-degrading antibodies in primary human microglia, NHP, and amyloid model; Co-IP of MS4A6A–DAP12 (preprint)

   PMID:bio_10.1101_2024.11.23.625001

   Open questions at the time

   • Preprint version not yet peer-reviewed at deposition
   • Stoichiometry and structural basis of the MS4A4A–MS4A6A–DAP12 axis undefined
4. 2025 High

   The peer-reviewed study confirmed the MS4A4A–MS4A6A–DAP12 axis as a cooperative post-transcriptional negative regulator of both transmembrane and soluble TREM2, limiting microglial viability, phagocytosis, and lysosomal function.

   Evidence Reciprocal Co-IP, CRISPR KO plus antibody degradation, multiple model systems, and TREM2/phagocytosis/lysosomal readouts

   PMID:41435829

   Open questions at the time

   • Structural model of how MS4A6A blocks DAP12-dependent TREM2 stabilization not resolved
   • Whether the DAP12 interaction underlies the mast-cell and endothelial roles is untested
5. 2025 High

   In vivo causality in amyloid pathology was untested; ortholog knockout showed MS4A6A loss reduces amyloid phagocytosis and disinhibits NF-κB-driven neuroinflammation, while overexpression promotes plaque-associated gene programs.

   Evidence Ms4a6d knockout in APP/PS1 mice with phagocytosis, plaque burden, NF-κB, and behavioral readouts plus overexpression in human microglia

   PMID:40877951

   Open questions at the time

   • Apparent contrast with the TREM2-restraining model not mechanistically reconciled
   • Direct link between NF-κB disinhibition and the DAP12/TREM2 axis not established
6. 2025 Medium

   Whether MS4A6A drives inflammation outside microglia was unknown; this work placed MS4A6A upstream of IKK/NF-κB in endothelial cells, promoting dysfunction and monocyte adhesion.

   Evidence siRNA silencing in ox-LDL-stimulated HUVECs with IKK inhibitor and IKK/IκBα epistasis plus ApoE-/- mouse model

   PMID:40090082

   Open questions at the time

   • Molecular link between MS4A6A and IKK activation not defined
   • Single-lab finding without independent replication
7. 2025 Medium

   Complementing the locus genetics, CRISPRi knockdown in hiPSC microglia showed MS4A6A restrains pro-inflammatory states and modulates the disease-associated microglia (DAM) response.

   Evidence CRISPRi/CROP-seq in hiPSC-derived microglia with ROS and single-cell cluster analysis (preprint)

   PMID:bio_10.1101_2025.03.09.642133

   Open questions at the time

   • Preprint, single lab
   • Effector pathway linking knockdown to DAM-cluster shift not defined
8. 2025 Low

   A coding/regulatory variant link to protein levels was needed; the rs7232 variant was associated with lower MS4A6A protein via proteasome-mediated degradation and altered plasma TREM2.

   Evidence Proteomics (OLINK), plasma TREM2 GWAS, and proteasome inhibition assays by rs7232 genotype

   PMID:41552371

   Open questions at the time

   • Method details sparse and not independently confirmed
   • Causal chain from genotype to TREM2 not directly demonstrated

• How MS4A6A reconciles its apparently opposing roles — restraining TREM2 signaling versus supporting amyloid phagocytosis and FcεRI/IKK-driven inflammation across cell types — remains unresolved.
• No structural model of the MS4A4A–MS4A6A–DAP12 complex
• Cell-type-specific determinants of pro- vs. anti-inflammatory output unknown
• Direct biochemical activity of MS4A6A beyond complex formation undefined